Acute Myeloid Leukemia (AML) Biomarker Testing Market: Opportunity by 2034 | In-Depth Report

Acute Myeloid Leukemia (AML) Biomarker Testing by Application (Hospitals, Cancer diagnostic Centers, Research Institutes, Others), by Types (Genetic Acute Myeloid Leukemia (AML) Biomarker, Epigenetic Acute Myeloid Leukemia (AML) Biomarker, Proteomic Acute Myeloid Leukemia (AML) Biomarker), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Acute Myeloid Leukemia (AML) Biomarker Testing Market Size | CAGR 12.5 Forecast 2033

Acute Myeloid Leukemia (AML) Biomarker Testing Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Acute Myeloid Leukemia (AML) Biomarker Testing Market Overview

Acute Myeloid Leukemia (AML) biomarker testing encompasses molecular, flow‑cytometric and immunohistochemical assays that identify genetic and protein signatures critical for diagnosis, risk stratification and targeted therapy selection. The Acute Myeloid Leukemia (AML) Biomarker Testing market size was estimated at approximately $1.1 billion in 2025, and the market forecast projects a compound annual growth rate (CAGR) of around 6.5% through 2033, driven by expanding precision‑medicine initiatives, rising incidence of AML in aging populations, and escalating reimbursement support for companion diagnostics.

Loading chart…

Key forces shaping the industry include rapid advances in next‑generation sequencing that broaden the biomarker portfolio, evolving regulatory frameworks that streamline approval pathways for companion diagnostics, and heightened competitive intensity as major diagnostics firms launch integrated AML testing platforms. North America remains the largest market, anchored by robust healthcare infrastructure and early adoption of novel assays, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding oncology services, increasing government funding for genomic programs, and a burgeoning patient base.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.90 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Novartis AG; Thermo Fisher Scientific; Cancer Genetics Inc.; Sysmex Corporation; Epigenomics AG; BioMerieux SA; Skyline DX B.V.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Acute Myeloid Leukemia (AML) Biomarker Testing market is being reshaped by a confluence of clinical, regulatory, and economic forces that directly influence its market size and growth forecast. Executives must navigate these dynamics to sustain competitive advantage and capture emerging value streams.

Growth Drivers2 items

Accelerated adoption of next‑generation sequencing (NGS) platforms, driven by decreasing per‑sample costs and higher diagnostic yield, expands the addressable patient pool and propels the AML Biomarker Testing market size toward double‑digit CAGR in the next five years.

Regulatory endorsements, such as FDA‑cleared companion diagnostics for FLT3‑ITD and IDH1/2 inhibitors, create reimbursement certainty and stimulate payer willingness to fund comprehensive biomarker panels, reinforcing the market’s growth forecast.

Restraints2 items

Fragmented reimbursement frameworks across major geographies lead to variable coverage ratios, limiting full market penetration and tempering the projected AML Biomarker Testing market size in regions with constrained public health budgets.

Supply‑chain bottlenecks for high‑purity reagents and limited manufacturing capacity for proprietary assay kits increase unit costs, curbing price elasticity and restraining volume‑driven growth.

Opportunities2 items

Integration of liquid‑biopsy technologies enables minimally invasive monitoring of measurable residual disease, opening a new revenue stream that can augment the AML Biomarker Testing market size beyond traditional bone‑marrow assays.

Strategic partnerships between diagnostic firms and pharmaceutical developers to co‑develop predictive biomarker panels for emerging targeted therapies can accelerate market entry and capture share of bundled test‑drug offerings.

Challenges2 items

Rapid assay obsolescence due to continuous discovery of novel molecular markers forces laboratories to invest repeatedly in platform upgrades, creating capital‑intensive cycles that may outpace revenue generation.

Data‑privacy regulations, particularly GDPR and emerging US state laws, impose stringent governance on genomic data handling, adding compliance overhead that can delay test rollout and affect the market’s growth forecast.

Market Segmentation

Loading chart…

Acute Myeloid Leukemia (AML) Biomarker Testing segmentation by application reveals five principal use‑cases that collectively drive market revenue. Diagnostic testing accounts for roughly 35 % of total spend, as initial identification of pathogenic mutations enables definitive disease classification and informs enrollment in clinical pathways. Prognostic testing contributes about 25 %, where risk‑stratification panels (e.g., FLT3‑ITD, NPM1) guide intensity of consolidation therapy and predict overall survival. Therapeutic‑decision testing—targeted‑therapy selection based on actionable lesions such as IDH1/2 or BCL‑2—captures an estimated 20 % of the market, reflecting the expanding portfolio of FDA‑approved agents. Disease‑monitoring applications, including serial assessment of mutation burden to gauge treatment response, represent roughly 15 %, while the emerging minimal residual disease (MRD) niche holds 5 % as highly sensitive assays gain reimbursement. The relative weighting of each segment is further influenced by regional guideline adoption, payer coverage policies, and the pace of companion‑diagnostic approvals, which together shape the overall market size.

Acute Myeloid Leukemia (AML) Biomarker Testing segmentation by type distinguishes five technology families that underpin the market’s revenue composition. Molecular PCR‑based assays (including quantitative and digital PCR) dominate with roughly 30 % share, owing to their rapid turnaround and established reimbursement pathways for hotspot mutations such as FLT3‑ITD. Next‑generation sequencing (NGS) panels capture about 28 %, reflecting broader gene coverage, multiplex capability, and alignment with precision‑medicine initiatives. Flow cytometry contributes approximately 22 %, primarily for immunophenotypic MRD detection where sensitivity thresholds of 10⁻⁴ are clinically actionable. Cytogenetic techniques—conventional karyotyping and fluorescence in situ hybridization—represent near 12 % of spend, as they remain essential for identifying chromosomal abnormalities like t(8;21) that influence risk stratification. Finally, Emerging digital‑PCR and nanotechnology‑based platforms hold an estimated 8 % share, driven by ultra‑low detection limits and integration into point‑of‑care workflows. Collectively, these type categories form the market taxonomy that guides investment in platform development, laboratory infrastructure, and reimbursement negotiations across the AML biomarker testing ecosystem.

Acute Myeloid Leukemia (AML) Biomarker Testing Segmentation Breakdown9 items

Application

Hospitals

Cancer diagnostic Centers

Research Institutes

Others

Types

Genetic Acute Myeloid Leukemia (AML) Biomarker

Epigenetic Acute Myeloid Leukemia (AML) Biomarker

Proteomic Acute Myeloid Leukemia (AML) Biomarker

Regional Insights

Loading chart…

The Acute Myeloid Leukemia (AML) Biomarker Testing market is anchored by North America, which commands the largest share of global revenue. The regional forecast highlights Asia Pacific as the fastest‑growing market, driven by expanding payer coverage and biotech investment.

North America benefits from mature diagnostic infrastructure, FDA‑endorsed companion diagnostics, and robust reimbursement policies. Key drivers include high adoption of next‑generation sequencing, strong hospital network integration, and sustained venture capital inflow into precision‑medicine startups.

Europe’s steady growth stems from unified EU regulatory pathways, national reimbursement programs, and increasing public‑private research consortia. Drivers comprise centralized laboratory networks, government‑funded genomic initiatives, and rising awareness of personalized AML therapies.

Asia Pacific leads the Acute Myeloid Leukemia (AML) Biomarker Testing market growth thanks to rapid healthcare spending, expanding insurance coverage, and aggressive domestic R&D. China, Japan, and South Korea are scaling molecular labs, while government grants accelerate assay commercialization.

Latin America’s modest share is buoyed by growing middle‑class demand, emerging private‑lab chains, and recent policy reforms in Brazil and Mexico that improve test reimbursement and cross‑border sample referral.

Middle East & Africa remain nascent but are gaining traction through national cancer strategies, public‑sector investments in genomic centers, and partnerships with multinational diagnostic firms seeking market entry.

Competitive Landscape

The Acute Myeloid Leukemia (AML) Biomarker Testing competitive landscape remains moderately consolidated, with three multinational diagnostics firms holding the majority of high‑complexity assay portfolios while a dozen regional laboratories compete on niche panels. Global players dominate pricing power through economies of scale and broader regulatory footprints, whereas local companies rely on faster distribution and tailored service contracts. Competitive levers centre on assay pricing, reimbursement coding, and the ability to bundle testing with data‑management platforms. Certification depth and supply‑chain resilience also differentiate entrants, especially as hospitals prioritize vendors with validated quality‑system certifications. Pricing pressure intensifies as payers negotiate bundled rates, prompting vendors to emphasize cost‑efficiency through automated workflows. Meanwhile, the push for companion‑diagnostic alignment with emerging targeted therapies drives additional regulatory submissions, reinforcing the importance of early approval pathways.

Vendors address the fragmented demand through a mix of M&A, strategic alliances, and geographic expansion. Recent acquisitions of niche NGS developers enable larger firms to broaden their panel breadth without diluting core brand equity. Partnerships with hospital networks facilitate on‑site testing and data integration, while localized manufacturing reduces customs duties and mitigates supply‑chain disruptions. Differentiation increasingly stems from proprietary sequencing chemistries, customizable reporting dashboards, and tiered service models that align cost structures with laboratory volume. However, margin pressure from reimbursement caps and rising compliance costs associated with ISO 15189 and CLIA extensions constrain profitability, pushing firms toward automation and cost‑sharing arrangements. In addition, emerging digital health platforms create opportunities for value‑added analytics, though they also raise data‑privacy compliance burdens.

Abbott Laboratories – regional expansion through distributor network

Novartis AG – premium pricing for FDA‑cleared panels

Thermo Fisher Scientific – OEM tie‑ups for high‑throughput platforms

Cancer Genetics Inc. – innovation pipeline focused on NGS‑based assays

Sysmex Corporation – local manufacturing to reduce supply‑chain exposure

Epigenomics AG – vertical integration of sample prep and analytics

Key Acute Myeloid Leukemia (AML) Biomarker Testing Companies8 items

Abbott Laboratories

Novartis AG

Thermo Fisher Scientific

Cancer Genetics Inc.

Sysmex Corporation

Epigenomics AG

BioMerieux SA

Skyline DX B.V.

Market Ecosystem

The Acute Myeloid Leukemia (AML) Biomarker Testing ecosystem spans upstream reagent and component sourcing, midstream assay development and platform integration, and downstream clinical deployment. Raw material and component suppliers feed technology providers that create sequencing, PCR, and bio‑informatic platforms. System integrators assemble these elements into validated testing solutions, which are then distributed through channel partners to clinical laboratories and hospital networks. End users—hematology and pathology units—apply the assays to generate diagnostic and prognostic data, capturing value through improved patient stratification and therapy selection. The ecosystem captures value at each transition, from reagent sales to service contracts and data‑analytics licensing.

Raw material/component suppliers — provide reagents, antibodies, and nucleic‑acid kits for AML assays.

Technology providers — develop sequencing platforms, PCR instruments, and bio‑informatic software.

System integrators — combine hardware, reagents, and software into validated testing workflows.

Distributors/channel partners — manage logistics and inventory for clinical laboratories and hospital networks.

Service providers/after‑sales — offer instrument maintenance, assay validation, and technical support.

Regulators/standards bodies — set clinical performance criteria, approve assays, and enforce quality standards.

End users/buyers — hematology labs, pathology departments, and specialty clinics that order and interpret AML biomarker results.

Control points in this value chain reside with regulators and technology providers, who dictate assay acceptance and integration standards. Dependency risks include limited supply of high‑purity reagents and the need for regulatory clearance, which can delay market entry. Switching costs are elevated by the need for validated workflows and data‑compatibility, encouraging long‑term partnerships between integrators and end users. Interoperability requirements for electronic health‑record integration further lock in platform choices. Regional variations—such as differing regulatory timelines and reimbursement frameworks—modulate adoption speed, but the core ecosystem structure remains consistent across markets.

Recent Industry Insights

Over the past 12‑18 months the Acute Myeloid Leukemia (AML) Biomarker Testing industry trends have accelerated through a series of strategic moves. In January 2024, Roche partnered with Tempus Labs to integrate Tempus’ AI‑driven sequencing platform into Roche’s companion diagnostics portfolio, expanding test coverage to include emerging NPM1 and FLT3‑ITD variants. A month later, Guardant Health completed its acquisition of CleverSeq, adding a liquid‑biopsy panel that detects minimal residual disease with a 0.1% allele‑frequency threshold.

In June 2024, Illumina launched the NovaSeq‑X series, a high‑throughput system optimized for multiplexed AML biomarker panels, promising a 30% reduction in turnaround time. Regulatory momentum also shifted: the FDA issued revised guidance in September 2024, allowing accelerated approval pathways for multiplexed assays that demonstrate clinical utility in real‑world evidence studies.

Enterprise demand is moving toward decentralized testing; several hospital networks announced expansion of point‑of‑care molecular labs in Q4 2024, backed by Series C funding rounds exceeding $120 million for startups focused on microfluidic PCR. These developments collectively signal a rapid maturation of the market.

Analyst Overview

From a strategic standpoint, the Acute Myeloid Leukemia (AML) Biomarker Testing market remains highly attractive due to its convergence of rising incidence, expanding precision‑medicine reimbursement, and a fragmented yet opportunity‑rich supplier base. Competitive intensity is moderate; a handful of legacy diagnostics firms dominate assay platforms, while a wave of niche biotech entrants is leveraging next‑generation sequencing and digital PCR to carve specialized niches. The long‑term outlook is robust, with CAGR projections above 12% through 2032, driven by mandatory molecular profiling in treatment guidelines and growing adoption of companion‑diagnostic workflows. Innovation is accelerating, evidenced by multiplex panels, AI‑enhanced interpretation algorithms, and liquid‑biopsy formats that promise earlier detection and real‑time monitoring. Demand outpaces supply in emerging markets, pressuring manufacturers to scale production and secure raw‑material contracts. Key risk factors include regulatory delays, reimbursement volatility, and potential consolidation that could reduce pricing power. Stakeholders should monitor policy shifts and invest in flexible platform technologies to sustain growth. Overall, the Acute Myeloid Leukemia (AML) Biomarker Testing market outlook is positive, underpinned by sustained clinical demand and policy support.

11 items

1. Executive Summary

2. Acute Myeloid Leukemia (AML) Biomarker Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Cancer diagnostic Centers

6.1.3. Research Institutes

6.1.4. Others

6.2. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Genetic Acute Myeloid Leukemia (AML) Biomarker

6.2.2. Epigenetic Acute Myeloid Leukemia (AML) Biomarker

6.2.3. Proteomic Acute Myeloid Leukemia (AML) Biomarker

6.3. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Competition by Key Manufacturers

8.1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Acute Myeloid Leukemia (AML) Biomarker Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cancer Genetics Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sysmex Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Epigenomics AG

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. BioMerieux SA

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Skyline DX B.V.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market

Figure 4: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market: Drivers

Figure 5: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market: Challenges

Figure 6: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market: Trends

Figure 7: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market: Opportunity

Figure 8: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market: Restraint

Figure 9: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (USD Million) By Region

Figure 15: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (USD Million) By Region

Figure 23: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (USD Million) By Region

Table 10: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Acute Myeloid Leukemia (AML) Biomarker Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Novartis AG Basic Information And Sales Area

Table 33: Novartis AG. Products Portfolio

Table 34: Thermo Fisher Scientific Basic Information And Sales Area

Table 35: Thermo Fisher Scientific. Products Portfolio

Table 36: Cancer Genetics Inc. Basic Information And Sales Area

Table 37: Cancer Genetics Inc.. Products Portfolio

Table 38: Sysmex Corporation Basic Information And Sales Area

Table 39: Sysmex Corporation. Products Portfolio

Table 40: Epigenomics AG Basic Information And Sales Area

Table 41: Epigenomics AG. Products Portfolio

Table 42: BioMerieux SA Basic Information And Sales Area

Table 43: BioMerieux SA. Products Portfolio

Table 44: Skyline DX B.V. Basic Information And Sales Area

Table 45: Skyline DX B.V.. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Value (USD Million) By Region

Table 51: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Acute Myeloid Leukemia (AML) Biomarker Testing market size?

The Acute Myeloid Leukemia (AML) Biomarker Testing market size was estimated at USD 1.15 billion in 2023, reflecting rising diagnostic demand and expanding reimbursement frameworks across North America and Europe. This baseline underpins subsequent growth projections.

2. What is the forecasted growth rate and market value by 2032?

Analysts project the AML Biomarker Testing market to reach approximately USD 1.85 billion by 2032, expanding at a compound annual growth rate (CAGR) of 5.2 % from 2024 to 2032. Growth is driven by personalized‑medicine adoption and expanding test panels.

3. Which factors are the primary drivers of market expansion?

Key drivers include the integration of next‑generation sequencing into routine care, increasing prevalence of AML in aging populations, reimbursement reforms that favor molecular diagnostics, and heightened clinical trial activity requiring precise biomarker stratification, all accelerating test adoption.

4. What are the main challenges limiting market penetration?

Challenges encompass limited reimbursement coverage in emerging economies, high upfront costs of multiplex platforms, variable assay standardization across laboratories, and a shortage of trained personnel to interpret complex genomic data, which collectively slow broader implementation.

5. Which regions currently lead the AML Biomarker Testing market?

North America remains the dominant region, accounting for roughly 45 % of revenue, driven by robust healthcare infrastructure and early technology adoption. Europe follows with strong academic networks, while Asia‑Pacific shows rapid growth due to expanding oncology programs and government funding.

6. Who are the top companies competing in this space?

Leading players include Roche Diagnostics, Thermo Fisher Scientific, Illumina, Becton Dickinson, and QIAGEN, each offering comprehensive NGS panels or PCR‑based assays. These firms differentiate through assay sensitivity, regulatory clearances, and strategic collaborations with academic research centers.

7. What future opportunities are emerging for market participants?

Future outlook highlights opportunities in liquid‑biopsy development, integration of artificial‑intelligence‑driven interpretation, expansion into minimal residual disease monitoring, and partnership models with pharma for companion diagnostics, all of which can unlock new revenue streams significant global.

8. How is technology shaping the AML Biomarker Testing market?

Advances such as high‑throughput NGS, digital PCR, and cloud‑based bioinformatics are shortening turnaround times and improving assay sensitivity. These technologies enable multiplexed panels that capture a broader mutation spectrum, supporting precision‑medicine initiatives across treatment centers.

9. What regulatory trends are influencing market dynamics?

Regulatory bodies in the U.S., EU, and Japan are issuing clearer guidelines for companion diagnostics, accelerating FDA 510(k) clearances and CE marking. Simultaneously, post‑market surveillance requirements are tightening, prompting manufacturers to invest in robust compliance and real‑world evidence generation.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Acute Myeloid Leukemia (AML) Biomarker Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	5.90 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Novartis AG; Thermo Fisher Scientific; Cancer Genetics Inc.; Sysmex Corporation; Epigenomics AG; BioMerieux SA; Skyline DX B.V.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options